Simplifying Global Compliance
FDA Begins Safety Review of Bleeding With BI’s Pradaxa
Washington Drug Letter
The FDA is reviewing postmarket reports of serious bleeding events in patients taking Boehringer Ingelheim’s blood-thinner Pradaxa just as the drug is facing increased competition with approval of Johnson & Johnson and Bayer’s Xarelto in atrial fibrillation (AF) patients.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing